LAUSR

Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale.

Sign Up to like & get
recommendations!
2 Published in 2022 at "Contemporary clinical trials"

DOI: 10.1016/j.cct.2021.106674

Abstract: BACKGROUND Despite dramatic increases in opioid use disorder (OUD) and overdose deaths, the U.S. has been unable to consistently deliver OUD treatment to those who need it. Syringe services programs (SSPs) can engage an out-of-treatment… read more here.

Keywords: risk; onsite buprenorphine; buprenorphine treatment; treatment ... See more keywords